Phospholipid Complex 30c

Orthoplex

Orthoplex Blue Phospholipid Complex offers a potent formulation of Phosphatidylserine for support of the brain and nervous system.

Gluten Free
Egg Free
Dairy Free
Vegan
Vegetarian
    Product Details

    Pack Size
    30 Capsule

    Adult Dose
    Take 1-2 capsules daily, or as recommended by your registered healthcare practitioner.

    BIO

    Storage
    Store below 25°C in a cool, dry place, away from direct sunlight.

    Indications

      • Phosphatidylserine is a phospholipid component of myelin
      • May help to support ageing brain function
      • May help to support the brain and nervous system
      • Phosphatidylserine is one of the most prevalent phospholipids in the brain

    Excipients
    Glycine, leucine, colloidal anhydrous silica, calcium phosphate, vegetable capsule (Vcaps®).

    Warning
    If symptoms persist, seek the advice of a healthcare professional.

    Ingredients

    Each capsule contains

    Soy phosphatidylserine-enriched soy lecithin powder 500.0mg
    Drug Interactions
    Significance
    Ingredient
    Interaction Descriptions
    Moderate
    PHOSPHATIDYLSERINE
    (Soy phosphatidylserine-enriched soy lecithin powder)
    Be cautious with this combination.
    View Interactions:
    Moderate

    CHOLINERGIC DRUGS

    Be cautious with this combination.

    Moderate

    CHOLINERGIC DRUGS

    Be cautious with this combination.

    Moderate

    CHOLINERGIC DRUGS

    Be cautious with this combination.

    Severity: moderate
    Occurrence: possible
    Level of Evidence: B

    Theoretically, phosphatidylserine might have additive effects with cholinergic drugs. <br> Phosphatidylserine is thought to increase acetylcholine levels (2437,8857,8858), which could theoretically lead to additive cholinergic effects when used with cholinergic drugs.

    References

    8857

    Kim HY, Akbar M, Lau A, et al. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem 2000;275:35215-23..

    8858

    Zanotti A, Valzelli L, Toffano G. Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats. Psychopharmacology (Berl) 1989;99:316-21..

    2437

    Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull 1992;28:61-6.

    Moderate

    ANTICHOLINERGIC DRUGS

    Be cautious with this combination.

    Moderate

    ANTICHOLINERGIC DRUGS

    Be cautious with this combination.

    Moderate

    ANTICHOLINERGIC DRUGS

    Be cautious with this combination.

    Severity: moderate
    Occurrence: possible
    Level of Evidence: B

    Theoretically, phosphatidylserine might decrease the effectiveness anticholinergic drugs. <br> Phosphatidylserine is thought to increase acetylcholine levels (2437,8857,8858), which could theoretically interfere with the activity of anticholinergic agents.

    References

    8857

    Kim HY, Akbar M, Lau A, et al. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem 2000;275:35215-23..

    8858

    Zanotti A, Valzelli L, Toffano G. Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats. Psychopharmacology (Berl) 1989;99:316-21..

    2437

    Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull 1992;28:61-6.


    Full Reference List

    8857
    Kim HY, Akbar M, Lau A, et al. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem 2000;275:35215-23..
    8858
    Zanotti A, Valzelli L, Toffano G. Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats. Psychopharmacology (Berl) 1989;99:316-21..
    2437
    Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull 1992;28:61-6.

    Rating System Description

    Level of Significance: Stop‑Light Rating System Occurrence/Severity
    Major

    Do not use combination; contraindicated; strongly discourage patients from using this combination; a serious adverse outcome could occur.

    Moderate

    Use cautiously or avoid combination; warn patients that a significant interaticon or adverse outcome could occur.

    Minor

    Be aware that there is a chance of an interaction; advise patients to watch for warning signs of a potential interaction.

    Likelihood of Occurrence

    Likely: Well‑controlled human studies have demonstrated existence of this interaction.

    Probable: Interaction has not been documented in well‑controlled studies, however interaction has been demonstrated in human studies or in controlled animal studies plus multiple case reports.

    Possible: Interaction has been documented in animal or in vitro research, or interaction has been documented in humans but is limited to case reports or conflicting clinical research.

    Unlikely: Interaction has been demonstrated in animal or in vitro research but has been shown not to occur in humans.

    Severity

    High: Life threatening or requires medical intervention to prevent a serious adverse event.

    Moderate: Worsened clinical status and/or requires medication adjustment.

    Mild: May cause minor clinical side effects. Unlikely to require medication adjustment.

    Insignificant: Drug or supplement levels may be affected but will not cause clinical effects.

    Level of Evidence

    A: High-quality randomized controlled trial(RCT).

    A: High-quality meta-analysis (quantitative systematic review)

    B: Nonrandomized clinical trial

    B: Nonquantitative systematic review

    B: Lower quality RCT

    B: Clinical cohort study

    B: Case-control study

    B: Historical control

    B: Epidemoilogic study

    C: Consensus

    C: Expert opinion

    D: Acecdotal evidence

    D: In vitro or animal study

    D: Theoretical based on pharmacology


    © 2019 TRC is a registered trademark of Therapeutic Research Center.
    TRC and all associated names and service marks including TRC are restricted and reserved for Therapeutic Research Center use.
    Natural Medicines™ and associated Natural Medicines product marks are trademarks of Therapeutic Research Center.

    Disclaimer: This information on interactions is licensed from the TRC Natural Medicines Database. Neither Bio Concepts nor TRC are providing medical, clinical or other advice and nothing should be interpreted as constituting such advice. Currently this does not check for drug-drug or supplementsupplement interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgement is necessary.